Neoplastic Disorder

12 Drugs classified under this biological system

Androgen Biosynthesis Inhibitor. Abiraterone Acetate 250 mg.
Tab 120 X 250 mg
1000 mg/d (4 tab.), once/d in comb. with oral prednisone 5 mg (twice/d for metast. CRPC and once/d for High risk mHSPC)
In comb. with prednisone for tmt. of metast. castr.-resist. prostate cancer (CRPC)
newly diagn. high risk metast. hormone-sensit. prostate
cancer (mHSPC) in adlt men in comb. with androgen depriv. ther.(ADT).  
C/I: Hypersens./Women/Sev. liver damage/In comb. with Ra-223

IgG2 kappa bispecific antibody. Elranatamab 40 mg/ml.
Vial with 44/76 mg  in sol. for SC inj. 40 mg/ml
Step-up doses of 12 mg on day 1 and 32 mg on day 4, followed by a full dose of 76 mg weekly from week 2 to week 24
as monother. for the tmt. of adlts. with relapsed and refractory multiple myeloma, who have received at least 3 prior ther., includ. an immunomodulatory agent, a proteasome inhib., and an anti-CD38 antibody and have demonstr. dis. progress. on the last ther.
C/I: Hypersens.

CD123-directed cytotoxin. Tagraxofusp 1.15 mg/vial.
CD123-directed cytotoxin tagraxofusp
 VIAL: conc. for sol. for infus. 1X  1 mg/ml
Admin. at 12 mcg/kg IV over 15 min. 1/d on days 1 to 5 of a 21-d
cycle. Dosing period may be extend. for dose delays up to day 10 of the cycle. Cont. until dis. progress. or unaccept. tox.
Tmt. of blastic plasmacytoid dendritic cell neoplasm
(BPDCN) in adults
C/I:Hypersens.

Immunoglobulins. Trastuzumab deruxtecan 20 mg/ml.
mAb linked to DXd, an exatecan deriv. and a
topoisomerase I inhibit.
Vial, 100 mg. Powd. for concentr. for sol. for inf.
 Breast or Lung cancer: 5.4 mg/kg bw once every 21 days
Gastric cancer: 6.4 mg/kg once every 21 days.
Do not substitute with trastuzumab or ado-trastuzumab emtansine.
HER2-Posit. Metast. Breast Cancer ; HER2-Low Metast. Breast Cancer; Unresect. or Metast. HER2-Mutant Non-Small Cell Lung Cancer; Locally Adv. or Metast. Gastric Cancer. See Lit
C/I:  Hypersens.

Monoclonal Antibody. Trastuzumab 150 mg, Trastuzumab 420 mg.
Vial:Pwd. for conc. for sol for infus.
Load: 4-8 mg/kg BW
Maint. 2-6 mg/kg BW weekly or at 3 weekly interval, see lit.
Tmt. of pts. with metast. breast cancer who have tumours that overexpress HER2; 1. As a sgle. agent, for the tmt. of those pts. who have received one or more chemother. regimens for their metast. dis..2. In combin. with Paclitaxel or Docetaxel for the tmt. of those pts. who have not received chemother. for their metastatic dis..3. In comb. with an aromatase inhib. for tmt. of postmenopausal ptt. with hne.-receptor posit. metast. breast cancer. See Lit
C/I: Hypersens. Sev. dyspnea at rest.

Human Monoclonal Antibody, Immunoglobulins. Durvalumab 50 mg/ml.
Vial:  Sol for inf.120/500 mg
Dosage and freq. depend on patient weight, disease type and monoor combined ther. See lit.
Urothelial Carcinoma: for pts with PD-L1 high (Tumor cell ≥25% or IC ≥25%) locally adv. or metast. urothelial carcinoma who:
- have dis. progr. during or following platinum-contain. chemother
. - have dis. progr. within 12 months of neoadj. or adj. tmt with platinum cont. chemother..
Non-Small Cell Lung Cancer - for pts with unresect. Stage III non-small cell lung cancer (NSCLC) whose dis. has not progr. following concurr.platinum-based chemother. and radiation ther.- in comb. with tremelimumab and platinum-based chemother. for the first-line tmt. of adlts with metast. NSCLC with no sensit. EGFR mutat. or ALK pos. mut..
Small Cell Lung Cancer, in combin. with etoposide and either carboplatin or cisplatin, for the first-line tmt. of adlt pts. with extens.-stage small cell lung cancer (ES-SCLC).
Biliary Tract Cancers: in comb. with gemcitabine and cisplatin for the first-line tmt of adlts with locally adv., unresect., or metast. biliary tract cancer (BTC).
Hepatocellular Carcinoma: in comb. with tremelimumab for the first line tmt of adlts with adv. or unresect. hepatocellular carcinoma (HCC).
C/I:  Hypersens.